Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. Issue 9 (24th July 2018)

• Record Type: Journal Article
• Authors: McCuaig, Jeanna M; Stockley, Tracy L; Shaw, Patricia; Fung-Kee-Fung, Michael; Altman, Alon D; Bentley, James; Bernardini, Marcus Q; Cormier, Beatrice; Hirte, Hal; Kieser, Katharina; MacMillan, Andree; Meschino, Wendy S; Panabaker, Karen; Perrier, Renee; Provencher, Diane; Schrader, Kasmintan A; Serfas, Kimberly; Tomiak, Eva; Wong, Nora; Young, Sean S; Gotlieb, Walter Henri; Hoskins, Paul; Kim, Raymond H
• Other Names: author non-byline.; Dornan Kimberly author non-byline.; Farag Maria author non-byline.; Ghatage Prafull author non-byline.; Grover Kelly author non-byline.; Hawrysh Andrea author non-byline.; Mcgee Jacob author non-byline.; Schindeler Karen author non-byline.; Speevak Marsha author non-byline.; Vaags Andrea author non-byline.; Vandersteen Anthony author non-byline.; Altman Alon author non-byline.; Baines Kelly-Ann author non-byline.; Bentley James author non-byline.; Bernardini Marcus author non-byline.; Cormier Béatrice author non-byline.; Dawson Lesa author non-byline.; Fung-kee-fung Michael author non-byline.; Giede Christopher author non-byline.; Gotlieb Walter author non-byline.; Hoskins Paul author non-byline.; Hirte Hal author non-byline.; Kieser Katharina author non-byline.; Foulkes Will author non-byline.; Lapointe-Milot Korine author non-byline.; Lau Susie author non-byline.; Miller Dianne author non-byline.; Power Patti author non-byline.; Provencher Diane author non-byline.; Salvador Shannon author non-byline.; Samouëlian Vanessa author non-byline.; Tonkin Katia author non-byline.; Zeng Ziggy author non-byline.; Grafodatskaya Daria author non-byline.; Kamel-Reid Suzanne author non-byline.; Meschino Wendy author non-byline.; Penney Lynette author non-byline.; Somerville Martin author non-byline.; Stockley Tracy author non-byline.; Tomiak Eva author non-byline.; Young Sean author non-byline.; Baret Laurence author non-byline.; Macmillan Andrée author non-byline.; Mccuaig Jeanna author non-byline.; Panabaker Karen author non-byline.; Serfas Kim author non-byline.; Wong Nora author non-byline.; Djordjevic Bojana author non-byline.; Shaw Patricia author non-byline.; Baugh Elisabeth author non-byline.; Chong George author non-byline.; Kotsopoulos Janet Girouxjoanne author non-byline.; Lo Bryan author non-byline.; Metcalfe Kelly author non-byline.; Perrier Renée author non-byline.; Power Joanne author non-byline.; Sadikovic Bekim author non-byline.; Schrader Kasmintan A author non-byline.; Sun Sophie author non-byline.; Thomas Heidi author non-byline.; Chodirker Bernie author non-byline.; Green Jane author non-byline.; Grafodatskaya Daria author non-byline.; Mccready Elizabeth author non-byline.; Mcgowan-Jordan Jean author non-byline.; Kim Raymond author non-byline.; Smith Amanda author non-byline.;
• Is Part Of: Journal of medical genetics. Volume 55:Issue 9(2018)
• Page Start: 571
• Page End: 577
• Publication Date: 2018-07-24
• Subjects: brca -- genetic counselling -- genetic testing -- ovarian cancer; Medical genetics -- Periodicals; 616.042
• DOI: 10.1136/jmedgenet-2018-105472
• Languages: English
• ISSNs: 1468-6244

Abstract

Abstract : The landscape of genetic testing in ovarian cancer patients has changed dramatically in recent years. The therapeutic benefits of poly ADP-ribose polymerase (PARP) inhibitors in treatment of BRCA1/2 -related ovarian cancers has resulted in an increased demand and urgency for genetic testing results, while technological developments have led to widespread use of multi-gene cancer panels and development of tumour testing protocols. Traditional genetic counselling models are no longer sustainable and must evolve to match the rapid evolution of genetic testing technologies and developments in personalized medicine. Recently, representatives from oncology, clinical genetics, molecular genetics, pathology, and patient advocacy came together to create a national multi-disciplinary Canadian consortium. By aligning stakeholder interests, the BRCA Testing to Treatment (BRCA TtoT) Community of Practice aims to develop a national strategy for tumour and germline BRCA1/2 testing and genetic counselling in women with ovarian cancer. This article serves to provide an overview of the recent evolution of genetic assessment for BRCA1/2 -associated gynecologic malignancies and outline a Canadian roadmap to facilitate change, improve genetic testing rates, and ultimately improve outcomes for hereditary ovarian cancer patients and their families.